3SBio Inc1530
▲ PositiveCapitalrelevance
Reports 26.5% adjusted profit growth and strong financials.
Impact on stocks 1
Biotech & Genomic Medicine
3SBio Inc3S Bio Reports 2026 Interim Results with 26.5% Adjusted Profit Growth
Earnings
3S Bio announced its interim results for the first half of 2026, recording revenue of RMB 4.53 billion, up 3.9% year-over-year, and adjusted operating net profit attributable to shareholders of the parent of RMB 1.44 billion, up 26.5%. Net profit attributable to equity holders reached RMB 1.15 billion, while R&D expenses rose 24.9% to RMB 680 million. The company obtained marketing approvals for core products in 23 countries and saw overseas product sales surge 43% year-over-year. Three Class 1 innovative drugs were approved for marketing during the period, and five products advanced to the New Drug Application stage. The company's financial resources totaled RMB 19.4 billion.
3SBio IncReports 26.5% adjusted profit growth and strong financials.